Compare iShares MSCI France ETF (EWQ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI France ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI France ETF trades at $45.16, while Medpace Holdings Inc trades at $535.89 (market cap $15.11B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI France ETF nearer its low. Which is the better fit depends on your goals.
| EWQ | MEDP | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $48.35 | $620.59 |
52-Week Low | $41.43 | $308.88 |
Market Cap | — | $15.11B |
Enterprise Value | — | $14.58B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI France ETF (EWQ) is trading at $45.16, up 0.27% on the day, while exhibiting a bearish technical signal with 11 sell signals versus 6 buy signals. The fund faces headwinds from European Central Bank rate hikes and energy market volatility driven by Middle East tensions, though it offers exposure to French technology investments and a scheduled $1.09 dividend in June 2026.
Outlook remains cautious amid macroeconomic uncertainty, with investment opportunity tied to France's €13 billion tech sovereignty push and AI investments, balanced against risks from energy price shocks, potential job losses in key EU sectors, and geopolitical trade tensions that could impact European equities.
MEDP trades at $539.39, up 0.6% today, with a bullish technical outlook supported by moving averages and a neutral RSI. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 results pending. Revenue grew to $2.53B in 2025, and net income margins remain strong at 17.19%, though valuation ratios like P/E of 33.31 suggest premium pricing. Recent news highlights volatility and a class action lawsuit filed in June 2026.
Outlook: MEDP shows robust profitability and growth potential, but high valuations and legal risks warrant caution. Analyst consensus is mixed with a $497 price target below current levels, indicating limited upside. Key catalysts include Q2 2026 earnings on July 22, 2026, which could drive momentum if results exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI France ETF
EWQ is a country-specific ETF that tracks the performance of the French equity market. It provides exposure to major global brands across sectors like luxury goods, industrials, and healthcare, including LVMH, Schneider Electric, and Hermes.
Read more on EWQ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
